Skip to main content
. Author manuscript; available in PMC: 2013 Aug 17.
Published in final edited form as: Cell. 2012 Aug 17;150(4):842–854. doi: 10.1016/j.cell.2012.07.023

Figure 6. Tumor-penetrating nanocomplex-mediated delivery of PSMC2-specific siRNA suppresses ovarian tumor growth.

Figure 6

A. Schematic depicting the mechanism of tumor-penetrating nanocomplex (TPN)-mediated delivery of siRNA. B. Comparison of cellular uptake of fluorescently labeled siRNA in untreated cells (solid grey) and cells treated with TPN alone (black line) and in combination with IgG (grey line) or an antibody to p32 (solid pink). C. Tumor burden of mice bearing disseminated OVCAR8 (top) or A2780 (bottom) orthotopic xenografts treated with TPN carrying either GFP-siRNA or PSMC2-siRNA. n=5 animals per group. D. PSMC2 levels in orthotopic tumors of A2780 or OVCAR8 after treatment with nanoparticles carrying siGFP or siPSMC2. E. Tumor burden of mice bearing orthotopic tumors of OVCAR8 cells expressing V5-PSMC2. n =5 animals per group. F. Tumor burden (top) and overall survival (bottom) of mice bearing orthotopic tumors of A2780 cells expressing doxycycline-inducible shRNA against PSMC2. n = 5–13 animals per group. Data in all panels presented as average ± S.E.M. Significance was determined by one-way ANOVA or Log-rank (Mantel-Cox) tests as appropriate. n.s. = not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. See also Figure S6.